Australian Regulators Advised To Reduce Complexities With Medical Cannabis Licensing Requirements

A recent government-commissioned report by Canberra’s Australian National University’s law professor, John McMillan, lists a number of recommendations to help the medical cannabis industry in Australia reports Marijuana Business Daily.

McMillan was supposedly hired to look closely at the regulatory barriers that the medical cannabis industry in Australia faces. One of the major concerns for the country rests in the ratio of actual licenses approved and total applications received, making the figure very small.

For instance, of the 246 license applications submitted this summer alone, only 24 licenses have allegedly been granted, with 16 for research and 23 for manufacturing purposes. This is apparently only the beginning of a long list of things officials need to consider.

Here is an overview of the recommendations provided in relation to medical cannabis by McMillan:

  1. Combine cultivation, manufacturing and research licenses into one license to reduce complexity in requirements and extraneous paperwork.

As per McMillan, this would eliminate, “information overload,” which otherwise results in the “(Office of Drug Control) ODC taking close to two years to process applications.”

  1. Extend the expiry dates on medical cannabis, research and manufacturing licenses to a maximum of five years
  2. Reassess ODC’s procedures to meet the need of existing license holders
  3. Creating a system in which those who already hold a medical cannabis license can easily get a manufacturing license
  4. Setting up industry consultation forums

The report doesn’t stop there, as the law professor also made recommendations regarding the country’s perspective on cannabidiol (CBD). In particular, he wants CBD to be de-scheduled from the 2016 Narcotic Drugs Regulation, so that an ODC licence is not required for the use of pure CBD as an ingredient.

On that note, McMillan urges that the improvements be made “as early as practicable.” When the news outlet reached out to the professor regarding his comment on timing, he simply said:

“I will leave it to the government to decide whether and how to implement my recommendations.”

Mandi Fuller

Mandi brings an uplifting presence with universal experience to the COR team by hosting an honorable 11-year track record of elbow-greased content writing while adding in 20 years of expertise in business administration. This unique combination of wit and will is exactly what makes this site and all of our valued readers so special.

Share

Recent Posts

  • Gummies

Condor CBD Gummies – Shocking Customer Scam Concerns?

The Condor CBD Gummies have been the talk of the hemp-derived cannabidiol edibles as of…

2 years ago
  • Guides

Best Delta 8 THC Products – And Why You Need To Try Them

Delta 8 THC is a naturally occurring cannabinoid commonly produced from hemp-derived CBD. It’s relatively…

3 years ago
  • Guides

VidaCap: What To Know About the Best Mushroom Supplements Brand

With more people turning towards natural remedies in recent years, mushroom supplements have taken the…

3 years ago
  • Topicals & Salves

Circle Labs CBD: Legit Hemp Pain Relief Balm That Works?

The Circle Labs CBD Balm is extracted using a cold-infusion process and is an effective…

3 years ago
  • Gummies

Kara’s Orchards CBD Gummies: Safe Full Spectrum Hemp Extract

If anyone is looking for a CBD supplement that is packed with all the necessary…

3 years ago
  • Tinctures & Drops

Sage Elixir CBD: Legit Sage Elixir CBD Oil Tincture or Not?

If anyone has been searching the internet for all the benefits of CBD and where…

3 years ago